Change in sexual dysfunction with aripiprazole: a switching or add-on study
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Sexual dysfunction and raised prolactin are common adverse effects of many anti-psychotics. Aripiprazole is an atypical anti-psychotic associated with a reduction in prolactin level in anti-psychotic-induced hyperprolactinemia. Our hypothesis was that switching from another anti-psychotic to aripiprazole would be associated with a reduction in sexual dysfunction. An open label switch to aripiprazole was offered to 27 subjects with inadequate therapeutic response or intolerance to another anti-psychotic, who were followed up for 26 weeks. Serial clinical ratings included the Anti-psychotic Non-Neurological Side-Effects Rating Scale (ANNSERS), and the Sexual Functioning Questionnaire. Our primary analysis point was week 12. In both sexes, there was a significant reduction in prolactin by week 12 ( P = 0.003), accompanied by a significant improvement in libido ( P = 0.028). In males, both erectile and ejaculatory difficulties were also significantly reduced ( P = 0.04 and P = 0.017, respectively). In females, menstrual dysfunction was also significantly reduced at week 12 ( P = 0.04). By week 26, the changes in all of the above remained significant, and were accompanied by a significant increase in satisfaction in overall sexual functioning ( P = 0.007), despite the fact that 54.5% of subjects at were also taking their original antipsychotic. There was also a significant decrease in the total ANNSERS score ( P < 0.001) and a significant improvement in all other measures of psychopathology (PANSS, CGI-S/I, GAF-S/D, and QoL). We conclude that switching to aripiprazole or the addition of aripiprazole to another antipsychotic regime is associated with a reduction in sexual dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?
O'Keane, V., & Meaney, A. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150223.31007.e0 · Cited by 307
Self-citationSexual dysfunction in patients taking conventional antipsychotic medication
Smith, S., O'Keane, V., & Murray, R. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.181.1.49 · Cited by 256
Self-citationSexual dysfunction and antipsychotic treatment
Cutler, A. J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00113-0 · Cited by 176
Dossenbach, M., Dyachkova, Y., Pirildar, S., Anders, M., Khalil, A., Araszkiewicz, A., Shakhnovich, T., Akram, A., Pecenak, J., McBride, M., et al. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2005.12.005 · Cited by 121
Howes, O. D., Wheeler, M. J., Meaney, A.-M., O'Keane, V., Fogelman, I., Blake, G., Murray, R. M., & Smith, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162798.87249.4d · Cited by 64
Self-citation
Cited by
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
Women’s sexual dysfunction associated with psychiatric disorders and their treatment
Basson, R., & Gilks, T. (2018) · Women's Health · doi:10.1177/1745506518762664 · Cited by 225
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Montejo, Á. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., Del Pino-Montes, J., García-Escudero, M. A., García-Rizo, C., González-Pinto, A., et al. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.02.003 · Cited by 75
Metadata
- Authors
- Mir, A., Shivakumar, K., Williamson, R. J., McAllister, V., O'Keane, V., & Aitchison, K. J.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-02-28
- Volume
- 22
- Issue
- 3
- Pages
- 244-253
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1978123597
- Cited by
- 86
- References
- 5
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.